UDCA has, therefore, been evaluated for the treatment of patients with PSC. Trials of UDCA at low doses (10–15 mg/kg per day and 17–20 mg/kg per day) have yielded inconclusive results in ...

Degree of benefit with UDCA is uncertain. Aim: To Look at Mode of diagnosis for CFALD and Effectiveness & safety of UDCA in our unit. Methods: Retrospective review on all patients currently ...

Ursodeoxycholic acid (UDCA) is the therapeutic agent most widely used for the treatment of cholestatic hepatopathies of diverse etiologies and has been mainly used as a supportive treatment in ...